<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02557334</url>
  </required_header>
  <id_info>
    <org_study_id>PKE STRAW II</org_study_id>
    <nct_id>NCT02557334</nct_id>
  </id_info>
  <brief_title>Effects of Freeze Dried Strawberry Powder Supplementation on Vascular Function and Blood Markers of Cardiovascular Risk</brief_title>
  <official_title>Effects of Freeze Dried Strawberry Powder Supplementation on Vascular Function and Blood Markers of Cardiovascular Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Penn State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>California Strawberry Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Penn State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of freeze dried strawberry powder on LDL
      cholesterol, central and peripheral blood pressure, indices of arterial stiffness, and other
      lipid and lipoprotein concentrations. The investigators hypothesize that the bioactive
      compounds in freeze dried strawberry powder may elicit beneficial effects on LDL cholesterol,
      as well as blood pressure and arterial health.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study design is a 3-period randomized crossover dose-response study to evaluate
      the effect of freeze dried strawberry powder supplementation on LDL-C and vascular health.
      Research participants will be overweight or obese (BMI 25-39 kg/m^2) but otherwise healthy
      adults with moderately elevated LDL-C (&gt;116 mg/dL or &gt;3.0mmol/L), blood pressure &lt;160/100
      mmHg, total cholesterol below 273 mg/dL for men and below 284 mg/dL for women, and
      triglycerides below 350 mg/dL. Subjects will be randomly assigned to three supplementation
      periods: 1) low dose freeze dried strawberry powder (13 g/d); 2) high dose freeze dried
      strawberry powder (40 g/d); and 3) a placebo powder. Each powder will be provided for 4-6
      weeks, separated by a 2-week washout period between treatment periods. Baseline and endpoint
      testing will include blood collection and vascular testing.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LDL-C</measure>
    <time_frame>Change from baseline after 4 week treatments of low dose, high dose, and placebo strawberry beverage</time_frame>
    <description>LDL-C values calculated using the Friedewald equation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central Blood Pressure</measure>
    <time_frame>Change from baseline after 4 week treatments of low dose, high dose, and placebo strawberry beverage</time_frame>
    <description>Aortic (central) blood pressure measured using the SphygmoCor System</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral Blood Pressure</measure>
    <time_frame>Change from baseline after 4 week treatments of low dose, high dose, and placebo strawberry beverage</time_frame>
    <description>Peripheral blood pressure measured using the SphygmoCor System</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Augmentation Index</measure>
    <time_frame>Change from baseline after 4 week treatments of low dose, high dose, and placebo strawberry beverage</time_frame>
    <description>Augmentation index measured using the SphygmoCor System</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse Wave Velocity</measure>
    <time_frame>Change from baseline after 4 week treatments of low dose, high dose, and placebo strawberry beverage</time_frame>
    <description>Pulse wave velocity measured using the SphygmoCor System</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol</measure>
    <time_frame>Change from baseline after 4 week treatments of low dose, high dose, and placebo strawberry beverage</time_frame>
    <description>Total cholesterol values determined by enzymatic procedures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>Change from baseline after 4 week treatments of low dose, high dose, and placebo strawberry beverage</time_frame>
    <description>Triglyceride values determined using enzymatic procedures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL-C</measure>
    <time_frame>Change from baseline after 4 week treatments of low dose, high dose, and placebo strawberry beverage</time_frame>
    <description>HDL-C will be estimated according to the modified heparin-manganese procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidized LDL (oxLDL)</measure>
    <time_frame>Change from baseline after 4 week treatments of low dose, high dose, and placebo strawberry beverage</time_frame>
    <description>Plasma concentrations of oxLDL will be measured using ELISA kits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malondialdehyde (MDA)</measure>
    <time_frame>Change from baseline after 4 week treatments of low dose, high dose, and placebo strawberry beverage</time_frame>
    <description>MDA will be measured using the thiobarbituric acid reactive substances (TBARS) assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Sensitivity C Reactive Protein (hs-CRP)</measure>
    <time_frame>Change from baseline after 4 week treatments of low dose, high dose, and placebo strawberry beverage</time_frame>
    <description>hs-CRP will be measured by latex-enhanced immunonephelometry</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Low Dose Strawberry Powder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 g composed of 13 g freeze dried strawberry powder + 27 g placebo powder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Strawberry Powder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 g freeze dried strawberry powder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Powder</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>40 g color and taste matched placebo powder</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Low Dose Strawberry Powder</intervention_name>
    <description>40 g composed of 13 g freeze dried strawberry powder + 27 g placebo powder</description>
    <arm_group_label>Low Dose Strawberry Powder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>High Dose Strawberry Powder</intervention_name>
    <description>40 g freeze dried strawberry powder</description>
    <arm_group_label>High Dose Strawberry Powder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo Powder</intervention_name>
    <description>40 g color and taste matched placebo powder</description>
    <arm_group_label>Placebo Powder</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women 35-65 years of age

          2. BMI ≥ 25 and ≤ 39 kg/m^2

          3. LDL-C &gt; 116 mg/dL

          4. Total Cholesterol below 273 mg/dL for men and below 284 mg/dL for women

          5. Triglycerides below 350 mg/d

          6. Non-smokers

          7. Blood pressure &lt; 160/100 mmHg

        Exclusion Criteria:

          1. History of acute or chronic inflammatory conditions or heart disease, kidney disease,
             liver disease, autoimmune disorders, or thyroid disease (unless controlled by
             medication and blood results within the previous 6 months are provided)

          2. History of diabetes mellitus (and/or a fasting glucose &gt; 126 mg/dL at screening)

          3. Stage II hypertension (blood pressure ≥ 160/100 mmHg)

          4. Lactation, pregnancy, or desire to become pregnant during the study

          5. Unwillingness to discontinue nutritional supplements, herbs, or vitamins, unless
             approved by investigator

          6. Use of medications/supplements for elevated lipids, blood pressure, or glucose

          7. Chronic use of non-steroidal anti-inflammatory or immunosuppressant medication

          8. Conditions requiring the use of steroids

          9. Unwillingness to refrain from blood donation prior to and during the study

         10. Any medical condition or abnormal laboratory value that is judged clinically
             significant by an investigator

         11. Allergy or sensitivity to strawberries or any ingredient in the study powders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Penny Kris-Etherton, PhD, RD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Danette Teeter, BS</last_name>
    <phone>814-863-8622</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Penn State CRC</name>
      <address>
        <city>University Park</city>
        <state>Pennsylvania</state>
        <zip>16803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danette Teeter, BS</last_name>
      <phone>814-863-8622</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2015</study_first_submitted>
  <study_first_submitted_qc>September 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2015</study_first_posted>
  <last_update_submitted>January 11, 2018</last_update_submitted>
  <last_update_submitted_qc>January 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Penn State University</investigator_affiliation>
    <investigator_full_name>Penny Kris-Etherton</investigator_full_name>
    <investigator_title>Distinguished Professor of Nutrition</investigator_title>
  </responsible_party>
  <keyword>Strawberry Powder</keyword>
  <keyword>Cardiovascular Disease Risk Factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

